Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 CAD | 0.00% | -3.46% | +20.25% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.25% | 111M | |
+15.65% | 69.91B | |
+2.72% | 25.14B | |
+5.62% | 8.32B | |
+6.10% | 8.07B | |
-21.85% | 7.97B | |
+0.73% | 4.56B | |
+17.40% | 4.31B | |
-0.14% | 3.99B | |
-2.34% | 3.87B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Obtains Public Reimbursement for Vascepa in New Brunswick and with other Public Payors